Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODM-201 plus ADT and docetaxel in metastatic castration-sensitive prostate cancer
CTR20160361Phase 3Completed
- Sponsor
- Bayer
- Start
- Mar 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of darolutamide in prostate cancer (PCa), prostate adenocarcinoma, sponsored by Bayer. Started Mar 2017; status: completed.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)prostate adenocarcinoma
Beyond the preview
Go deeper on CTR20160361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160361.